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a b s t r a c t
Expression of the constitutive androstane receptor (CAR, NR1I3) is enriched in the mature mammalian
liver and increasingly recognized for its prominent role in regulating a myriad of processes including
biotransformation, chemical transport, energy metabolism and lipid homeostasis. Previously, we
demonstrated that CAR levels were markedly enhanced during the differentiation of hepatic-like cells
derived from hESCs, prompting the hypothesis that CAR contributes a key functional role in directing
human hepatogenesis. Here we demonstrate that over-expression of CAR in human embryonic stem cells
(ESCs), transduced by a lentiviral vector, accelerates the maturation of hepatic-like cells, with CAR over-
expressing cells exhibiting a 2.5-fold increase in albumin secretion by day 20 in culture differentiation,
and signiﬁcantly enhanced levels of mRNA expression of several liver-selective markers, including
hepatic transcription factors, plasma proteins, biotransformation enzymes, and metabolic enzymes. CAR
over-expressing cells also exhibited enhanced CITCO-inducible CYP3A7 enzymatic activity. Knockdown
of CAR via siRNA attenuated the differentiation-dependent expression programs. In contrast, expression
levels of the pregnane X receptor (PXR), a nuclear receptor most similar to CAR in primary sequence,
were negligible in human fetal liver tissues or in the differentiating hESCs, and stable over-expression of
PXR in hepatic-induced hESCs failed to enhance expression of hepatic phenotype markers. Together,
these results deﬁne a novel role for human CAR in hepatic lineage commitment.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Differentiation of hESCs among hepatic lineage is typically
divided into four stages: endoderm induction (days 1–3), hepatic
speciﬁcation (days 4–8), hepatoblast expansion (days 9–13) and
hepatic maturation (days 14–20) (Snykers et al., 2009). These
processes are controlled by a myriad of speciﬁc molecular and
genetic signals that are the subject of active investigation. Recent
studies have focused on deﬁning the roles of key transcriptional
factors and other signaling pathways that drive the complex
process of hepatic differentiation. For example, transduction of
hepatocyte nuclear factor 4α (HNF4α) and co-transduction of
forkhead box A2 (FoxA2) and HNF1α appear to facilitate hepatic
differentiation from human embryonic stem cells (ESCs) and from
human induced pluripotent stem cells (hiPSCs) (Takayama et al.,
2012). Impressively, Huang et al. demonstrated that transduction
of GATA4, HNF1α and FoxA3, together with the inactivation of
p19ARf induces the development of mouse tail-tip ﬁbroblasts into
functional hepatocyte-like cells (Huang et al., 2011). Other
researchers have reported on a variety of matrices and culture
supplements to promote hepatic differentiation, including the use
of media containing ﬁbroblast growth factor (Agarwal et al., 2008;
Baharvand et al., 2006; Basma et al., 2009; Cai et al., 2007; Chiao
et al., 2008; Lavon et al., 2004; Schwartz et al., 2005; Shiraki et al.,
2008; Soto-Gutierrez et al., 2006), bone morphogenetic protein
(Cai et al., 2007), hepatocyte growth factor (Agarwal et al., 2008;
Baharvand et al., 2006; Basma et al., 2009; Chen et al., 2006; Hay
et al., 2008b; Ishii et al., 2008; Moore and Moghe, 2009; Schwartz
et al., 2005; Shiraki et al., 2008; Soto-Gutierrez et al., 2006),
dexamethasone (Agarwal et al., 2008; Baharvand et al., 2006;
Basma et al., 2009; Moore and Moghe, 2009; Shirahashi et al.,
2004; Shiraki et al., 2008; Soto-Gutierrez et al., 2006), insulin
(Baharvand et al., 2006; Shirahashi et al., 2004), oncostatin M
(Agarwal et al., 2008; Baharvand et al., 2006; Hay et al., 2008b;
Moore and Moghe, 2009; Shiraki et al., 2008), activin A (Agarwal
et al., 2008; Basma et al., 2009; Cai et al., 2007; Chen et al., 2006;
D’Amour et al., 2005; Hay et al., 2008a, 2008b; Ishii et al., 2008;
Moore and Moghe, 2009; Shiraki et al., 2008), wnt3a (Hay et al.,
2008a; Moore and Moghe, 2009), and sodium butyrate (Hay et al.,
2008b; Rambhatla et al., 2003). The review by Snykers et al. offers
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a comprehensive synopsis of the progress in driving hepatocyte
differentiation from hESCs (Snykers et al., 2009). While promising,
the differentiation methodologies deﬁned remain insufﬁcient to
derive fully functional hepatocytes from hESCs.
Previously, we deﬁned a hepatic differentiation approach
involving the culture of hESCs for 20 days on a collagen matrix
in the presence of a deﬁned hepatocyte culture medium (Zamule
et al., 2011). The resulting hepatic-like cell population exhibited
decreased expression of ‘stemness’ markers as well as enhanced
expression of a variety of hepatic transcription factors, nuclear
receptors, liver-generated plasma proteins, protease inhibitors,
metabolic enzymes, and biotransformation enzymes. Further,
these hESC-derived hepatic-like cells developed the capacity to
transport anionic compounds and store glycogen. Notably, expres-
sion of the constitutive androstane receptor was markedly
increased in the hepatic-like cells.
CAR is a member of the nuclear receptor (NR) superfamily and
is expression is highly enriched in the liver (Swales and Negishi,
2004). Subsequent to their activation, both CAR and the pregnane
X receptor (PXR) function as transcriptional regulators of genes
participating in hepatic biotransformation and drug transport
(Chang and Waxman, 2006), affecting the dispositional fate of
many drugs (Wei et al., 2000), chemical carcinogens (Xie et al.,
2003) as well as endogenous substances such as steroids (Xie
et al., 2003), heme and bilirubin (Xie et al., 2003), thyroid
hormone (Maglich et al., 2004), and cholesterol/bile acids (Guo
et al., 2003; Stedman et al., 2005). CAR's function has also emerged
as an important regulator of lipid and energy metabolism (Wada
et al., 2009) and as a modulator of genes involved in a diverse
array of physiological processes that include cell growth and
differentiation (Page et al., 2007; Liu et al., 2009; Baskin-Bey
et al., 2006; Blanco-Bose et al., 2008).
Evolving evidence supports the concept that the NRs function
as critical mediators in both the maintenance of ‘stemness’ as well
as in stem cell differentiation (Jeong and Mangelsdorf, 2009).
However, limited data exist regarding CAR's expression and its
potential role in the hepatic speciﬁcation process. A recent report
comparing expression levels of members of the NR superfamily
during embryoid body differentiation indicated that hESCs express
increasing levels of CAR during the ﬁrst six days of development
(Xie et al., 2009). These ﬁndings were corroborated in a 30-day
differentiation protocol reporting increased expression levels of
CAR in hepatic-like cells derived from hESCs (Ek et al., 2007).
In the developing liver, CAR mRNA expression correlates with that
of its transcriptional regulator, HNF4α (Pascussi et al., 2007), a NR
that plays an integral role in hepatic differentiation (Li et al.,
2000). Interestingly, despite inter-individual and developmental
stage variability, in a panel of human fetal liver samples CAR
mRNA expression levels in fetal liver averaged approximately 40%
that of postnatal liver levels and were approximately 4-fold
greater than that of HNF4α (Vyhlidal et al., 2006).
Given these observations, and considering our previous results,
we hypothesized that CAR contributes an important biological role
directing the differentiation of hESCs along the hepatic lineage. The
data presented here conﬁrm that CAR's expression is markedly
enhanced during the process of human hepatic differentiation.
More importantly, in differentiating hESCs, CAR over-expression
and conversely, its reduction, contributed major modulatory effects
on a battery of biochemical, molecular and functional hepatic
markers impacting a variety of developmental programs. In con-
trast to the contributions of CAR in human hepatic speciﬁcation,
PXR was expressed only marginally in hESCs or in human fetal liver
and its forced over-expression did not signiﬁcantly impact the level
of any hepatic-speciﬁcation marker tested. The results of the
current investigation support a critical role for CAR as a key
regulator in the complex scheme of human hepatic differentiation.
Materials and methods
Chemicals
Dimethyl sulfoxide (DMSO) was obtained from Sigma-Aldrich
(St. Louis, MO). Rifampicin (RIF) was purchased from VWR Bios-
ciences. 6-(4-chlorophenyl): imidazo[2,1-b]thiazole-5-carbalde-
hyde O-(3,4-dichlorobenzyl)oxime (CITCO) was obtained from
BIOMOL Research Laboratories (Plymouth Meeting, PA).
Human fetal tissues and primary hepatocyte cultures
Human fetal liver tissues were obtained from Dr. Thomas
Shepard from the Central Laboratory of Human Embryology at
the University of Washington, Seattle, WA. Cultures of primary
human hepatocytes were obtained from Dr. Stephen Strom from
the University of Pittsburgh through the Liver Tissue Procurement
and Distribution System (NIH Contract # N01-DK-7-0004/
HHSN267200700004C). Primary human hepatocytes were isolated
by a three-step collagenase perfusion technique and plated on rat-
tail collagen as described previously (Strom et al., 1996). Hepato-
cytes were maintained in William's E Media (Gibco; Grand Island,
NY) supplemented with 10 mM HEPES (Gibco), 2 mM GlutaMAX
(Gibco), 100 units/ml penicillin and 100 μg/ml streptomycin
(Gibco), 25 nM dexamethasone (Sigma; St. Louis, MO), 10 nM
insulin (Sigma), 5 ng/ml selenium (Sigma), 5 μg/ml transferrin
(Sigma), and 1% linoleic acid/albumin (Sigma) (Olsavsky et al.,
2007).
Human embryonic stem cell culture
The WA09 (H9) and WA01 (H1) human embryonic stem cell
lines were acquired from the National Stem Cell Bank through
WiCell Research Institute (Madison, WI). The cells were main-
tained on irradiated human foreskin ﬁbroblast (hFF) feeder layer
cells (ATCC; Manassas, VA) in hESC media consisting of Dulbecco's
Modiﬁed Eagle Media F-12 (Gibco) supplemented with 20% knock-
out serum replacement (Gibco), 1 mM GlutaMAX (Gibco), 0.1 mM
non-essential amino acids (Gibco), 25 ng/ml basic ﬁbroblast
growth factor (National Cancer Institute; Bethesda, MD), and
0.1 mM β-mercaptoethanol (Sigma). Media was changed daily
and differentiated colonies were removed from the culture by
manual dissociation 2–3 times per week, depending on the culture
density. Cells were passaged weekly by manual dissociation and
plated on fresh hFF feeder layers. The data presented were
generated from the H9 cell line; although analogous results as
tested were also obtained with the H1 cells (data not shown).
Hepatic differentiation of human embryonic stem cells and
treatments
Human embryonic stem cells (hESCs) were ﬁrst differentiated
into hepatic-like cells using hepatocyte media. Hepatocyte-like
morphology and hepatocyte-speciﬁc functions including inodcya-
nine green uptake and glycogen storage capacity were presented in
a previous report (Zamule et al., 2011). The data shown in
Figs. 5 and 6 C–E were generated based on this protocol. To further
optimize the stem cell differentiation strategy, various growth
factors were sequentially added, according to the methods of Cai
et al. (2007). Brieﬂy, culture plates were coated with a ice cold 2.4%
(v/v) of rat tail type I collagen (Sigma) in MCDI solution (N-
Cyclohexyl-N′-(2-morpholinoethyl) carbodiimide metho-p-toluene-
sulfonate, Sigma), incubated at 37 1C for 4 h and washed with PBS.
Initially, hESCs were plated on collagen-coated plates in hESC
media. After 1 day, knock-out serum replacement was reduced to
2% and supplemented with 100 ng/ml Activin A (Peprotech, NJ).
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After 3 days of Activin A treatment, the differentiated cells were
cultured in hepatocyte media (see above) containing 100 ng/ml
basic ﬁbroblast growth factor and 20 ng/ml bone morphogenic
protein2 (BMP2, Peprotech, NJ) for 5 days. The differentiated cells
were then incubated with hepatocyte media supplemented with
20 ng/ml hepatocyte growth factor (HGF, Peprotech, NJ) for 5 days.
Finally, hepatocyte maturation was further stimulated by culture in
hepatocyte media with 10 ng/ml oncostatin M (OSM, Peprotech, NJ).
Alkaline phosphatase staining
An alkaline phosphatase detection kit (Millipore) was used for
alkaline phosphatase staining, conducted essentially according to
the manufacturer's instructions. Brieﬂy, cells were ﬁxed with 4%
formaldehyde in PBS, rinsed with TBST (20 mM Tris–HCl, 0.15 M
NaCl, 0.05% Tween-20), stained for 15 min with a 2:1:1 ratio of
Fast Red Violet:Naphthol:water, rinsed with TBST, and covered
with PBS. Cells were visualized using a Nikon TE-2000 inverted
ﬂuorescent microscope (Nikon USA; Melville, NY) and images
were captured using a digital camera and SpotRT software (Diag-
nostic Instruments; Sterling Heights, MI).
Lentiviral cDNA and siRNA expression vector construction
Lentivectors were obtained from System Biosciences (Mountain-
view, CA). The pCDH1-MCS1-EF1-copGFP cDNA lentivector expres-
sing human CAR (NM_005122) and the pSIH1-H1-copGFP shRNA
lentivector expressing a small interfering RNA targeted to CAR were
generated as described previously (Zamule et al., 2008). The pCDH1-
MCS1-EF1-copGFP cDNA lentivector expressing human PXR
(NM_003889) was engineered as follows. Brieﬂy, PXR was PCR-
ampliﬁed from human liver cDNA using the primer sequences:
Forward, 5′-GATCGAATTCGACATGGAGGTGAGACCCAAAGAAAG-3′;
Reverse, 5′- GATCGATATC TAGAAGGCACAGTCGAGG-3′ (restriction
sites underlined). The amplicon and vector were then digested with
EcoRI/EcoRV and EcoRI/SwaI, respectively, electrophoresed through a
0.6% agarose gel, puriﬁed using QIAquick Gel Extraction Kit (Qiagen;
Valencia, CA), and cloned by ligation. Plasmids were puriﬁed using
QIAﬁlter Plasmid Maxi Kit (Qiagen) and sequence veriﬁed.
Lentiviral production and target cell infection
Production of lentiviral particles and target cell transductions
were performed according to the manufacturer's instructions
(System Biosciences) with minor adaptations. Brieﬂy, human
embryonic kidney (HEK) 293T/17 transformed virus packaging
cells (ATCC), cultured as previously described (Zamule et al.,
2008), were transfected with lentiviral expression plasmids and
pPACKH1 packaging plasmid mix (System Biosciences) using
Lipofectamine 2000 (Invitrogen; Carlsbad, CA). Pseudoviral super-
natants were collected from packaging cell cultures at 72 h post-
transfection, ﬁltered, and used for direct target cell infections in
the presence of 6 mg/ml polybrene. Target cell media was replaced
the following day. Transduction efﬁciency was assessed using
green ﬂuorescent protein as a marker for gene expression and
monitored with a Nikon inverted ﬂuorescence microscope. Images
were captured using a digital camera and SpotRT software.
RNA isolation from cultured cells and human fetal liver tissues, cDNA
archiving, and Taqman or SYBR green real-time PCR
RNA was isolated from cultured cells and human fetal liver
tissues, using TRIzol Reagent (Invitrogen) and converted to cDNA
using the High Capacity cDNA Archive Kit (Applied Biosystems;
Foster City, CA), both according to manufacturers' protocols. Real-
time RT-PCR was carried out using TaqmansGene Expression Assays
(Applied Biosystems), according to the manufacturer's instructions.
Brieﬂy, 50 ng of cDNA template, 15 μl 2 Taqman Universal Master
Mix, and 1.5 μl 20 Target Assay Mix were combined into 30 μl
reactions. Otherwise, real-time RT-PCR was performed with Per-
feCTa SYBR Green SuperMix, UNG, ROX (Quanta BioSciences,
Gaithersburg, MD). Fifty ng of cDNA template, 15 μl 2 SYBR green
Master Mix, 0.1 mM ﬁnal concentrations of forward and reverse
primers were added into 30 μl reactions. The reactions were divided
in half to generate technical replicates and run on a CFX96 Touch™
Real-Time PCR Detection System (Bio-Rad, Hercules, CA). Data were
analyzed using theΔΔCT method as previously described (Livak and
Schmittgen, 2001; Zamule et al., 2008). Standard curves were
generated by amplifying a serial dilution of plasmid DNA containing
CAR or PXR. A strong linear relationship between CT values (y) and
log of cDNA copy numbers (x) was observed between 30 and 3106
copies (y¼3.455 log10(x)þ37.169, r2¼0.999, 94.73% efﬁciency,
for CAR; y¼3.429 log10(x)þ35.762, r2¼0.999, 95.72% efﬁciency,
for PXR). All experiments were performed in accordance with the
Minimum Information for Publication of Quantitative Real-Time PCR
Experiment (MIQE) guidelines (Bustin et al., 2009). SYBR Green
Primers and Taqmans probes are summarized in Supplemental
Table 1.
Albumin secretion ELISA assay
Conditioned media from the differentiated hESCs was collected
at day 20 and stored at 80 1C until assayed. The concentration of
human albumin secreted into the cell culture medium was deter-
mined using a human albumin ELISA quantitation kit (Bethyl
Laboratory, Montgomery, TX, USA), according to the manufacturer's
instructions. Brieﬂy, the plate was prepared by incubating with the
human albumin coating antibody for 1 h, washed 5 times, incu-
bated with blocking solution containing 1% BSA for 30 min, and
then washed 5 times. Then, 100 μl of each standard, control, or
samples were loaded to each well and incubated for 1 h, followed
by 5 washes. The plate was incubated with HRP-conjugated human
albumin detection antibody for 1 h, washed 5 times, and immersed
in tetramethylbenzidine (TMB) substrate solution for 15 min in the
dark. Color development was stopped by addition of 0.18 M H2SO4.
The plate was read at 450 nm using a Packard Spectra Count
(Meriden, CT) reader. The concentration of human albumin was
normalized to the number of total cells determined from each well.
CYP activity assays
CYP3A4/7 and CYP2C9 activity were measured using the P450-
Glo™ CYP assay kit (Promega, WI). Intracellular CYP enzymes convert
the luminogenic substrate to the luciferin product, which is detected
in a subsequent reaction with the Luciferin Detection Reagent. The
amount of luminescence produced is directly proportional to CYP
activity. Brieﬂy, hepatic-like cells were incubated with the fresh
culture medium containing CYP3A4/7 or CYP2C9 pGlo substrates.
After incubation for 3–4 h at 37 1C, 50 μl of the medium from each
well was transferred to a 96-well opaque white luminometer plate
and 50 μl of luciferin detection reagent was added to initiate the
luminescent reaction. The plate was incubated at room temperature
for 20 min and luminescence was read using a Tecan Inﬁnite m200
Pro luminometer (Switzerland). Net signals were calculated by
subtracting background luminescence values from DMSO and NR
activators-treated values.
Statistical analyses
Data were generated from at least two independent trials, and
presented as mean7SEM. A Student's t-test (one-tailed; two-
sample, unequal variance) was used for two-group comparisons.
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One-way ANOVA with Tukey's analysis was used to compare the
means of three or more groups. A two-way ANOVA with Bonfer-
roni analysis was used to determine how a response was inﬂu-
enced by two factors. Statistical signiﬁcance was set as po0.05.
Results
Hepatic differentiation of hESCs results in increased CAR expression
Previously we demonstrated that culturing hESCs on a collagen
substrate within a highly-deﬁned culture media enabled the
differentiation of hepatic-like cells that exhibited enhanced
expression of selective markers including transcription factors,
nuclear receptors, plasma proteins, metabolic and biotransforma-
tion enzymes, as well as augmented hepatic functional indices
such as transport of anionic compounds and glycogen storage,
coincident with attenuated expression of pluripotency markers
and ‘stemness’ function (Zamule et al., 2011). In the current report,
the differentiation culture conditions were further optimized (see
Materials and methods) such that enhanced levels of CAR mRNA
were now detected in the developing hepatoblasts after 3 days of
culture, and these levels were further enhanced throughout the
extended study period, especially at the stages equivalent to
hepatic speciﬁcation (day 8) and hepatoblast expansion (day 13)
(Fig. 1A).
CAR expression in human fetal liver tissue
To determine the extent to which CAR is expressed in human
fetal liver, we quantiﬁed CAR mRNA levels in tissues acquired from
nine subjects encompassing a range of gestational stages. CAR
hepatic mRNA levels were relatively highly expressed late in the
ﬁrst trimester and early in the second trimester, although at levels
less than those measured in adult liver (Fig. 1B). These ﬁndings are
consistent with those previously reported by Vyhildal et al.
(Vyhlidal et al., 2006). Microarray expression data from a panel
of human tissue generated using Affy U95 (publicly available
through the UCSC Genome Browser website http://genome.ucsc.
edu/ (Karolchik et al., 2008; Kent et al., 2002)), further conﬁrms
that CAR mRNA is relatively robustly and selectively expressed in
fetal liver.
Lentivirus efﬁciently transduces hESCs and does not alter select
markers of ‘stemness’
To enable experimental analyses of CAR function in the stem
cell differentiation model, a stable genetic modulation system
utilizing lentivirus was deployed. Initially with this approach,
hESC colonies were transduced with lentivirus containing an
expression construct for green ﬂuorescent protein (GFP). Although
inter- and intra-colony variability in transduction efﬁciency was
noted, infected hESC colonies generally exhibited high levels of
GFP expression (Supplementary Fig. 1A, upper panels). The most
homogenously GFP-positive colonies were selected for subsequent
propagation. GFP expression was retained in infected hESCs for
over two months in culture (throughout six passages) in the
absence of selective pressures (Supplementary Fig. 1A, lower
panels). Although available data suggest that lentiviral infection
does not affect hESC pluripotency (Gropp et al., 2003; Xiong et al.,
2005), we examined this issue by quantifying the relative mRNA
expression levels of selected markers implicated in self-renewal
and pluripotency in lentivirus-infected hESCs. Infected hESC colo-
nies exhibited no morphological abnormalities or signs of toxicity.
Further, when compared to uninfected control cells, lentiviral
infection posed no detectable alteration of mRNA expression levels
for the ‘stemness’ markers, octamer-binding transcription factor 4
(OCT4), nanog homeobox (NANOG), SRY-box containing gene 2
(SOX2), alkaline phosphatase, or the tyrosine-protein kinase C-KIT
(Supplementary Fig. 1B). Conﬁrmation that lentivirus infection did
not alter alkaline phosphatase expression was attained at the
functional level using an alkaline phosphatase activity staining
technique (Supplementary Fig. 1C).
CAR expression enhances hepatic differentiation of hESCs
To determine the impact of CAR expression on hepatic differ-
entiation capacity, the lentivirus systemwas used to stably express
exogenous CAR in hESCs which were then subjected to the hepatic
differentiation protocol. These cells exhibited signiﬁcantly
increased expression of CAR mRNA compared with cells infected
with empty virus (Fig. 2A), without any accompanying noted
difference in morphology or viability changes that could be
observed. Stage-speciﬁc differentiation markers were examined
to allow assessment of the relative extent of hepatic cellular
differentiation and maturation. Transduced CAR-overexpressing
cells exhibited enhanced increased mRNA expression of the
hepatic transcription factors, CCAAT/enhancer binding protein
alpha (C/EBPα), HNF1α, and HNF4α (Fig. 2), representing primary
members of the combinatorial regulatory network that governs
transcription of most genes during and after hepatic speciﬁcation
(Kyrmizi et al., 2006). mRNA levels of α-fetoprotein (AFP), a
hepatic endoderm cells marker, were signiﬁcantly enhanced in
CAR infected cells on day 8, and progressively elevated until day
20 of culture differentiation. mRNA expression of albumin, a
hepatic progenitor cell marker, and AAT were initially detected
at day 13 in CAR over-expressing cells, reaching higher levels by
Fig. 1. CAR mRNA is expressed during hepatic differentiation. Real-time PCR was performed using cDNA prepared from (A) HESCs or differentiated stem cells at indicated
days, and (B) human fetal liver tissue or pooled samples from eight primary human hepatocyte donors (HH). Copy number was calculated based on the standard curve
generated by amplifying a dilution series of a standard plasmid DNA containing CAR. npo0.05.
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day 20 of culture (Fig. 2C). As well, the liver-selective metabolic
enzymes, 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2
(HMGCS2) and phosphoenolpyruvate carboxykinase (PEPCK) were
similarly enhanced by CAR expression, representing endpoints
primarily expressed during hepatoblast expansion and hepatic
maturation (Fig. 2D).
Effect of CAR expression on basal and inducible CYP450 mRNA
expression
Cytochrome P450s (CYP, phase I monooxygenase enzymes), in
particular CYP2B and CYP3A family members, are known as gene
targets of CAR and PXR. Further, the extent of CYP expression and
activity reﬂect in a functional respect the degree of liver maturation.
In cultured hESCs induced to differentiate along a hepatic lineage,
lentiviral transduction with exogenous CAR led to signiﬁcantly
increased basal expression of CYP450 mRNA expression, compared
to empty vector transduced cells. On day 20 of the differentiation
protocol, CYP2B6 mRNA levels was increased 15-fold in CAR
transduced cells compared with approximately 6-fold for the empty
vector cells (Fig. 3A). Further, after 20 days of differentiation
CYP3A4 and CYP3A7 expression were 39- and 30-fold elevated,
respectively, in the CAR transduced hepatic-like cells compared
with non-transduced cells (Fig. 3B and C). To study the effect of NR
activator treatment on CYP mRNA expression, differentiated hESCs
with or without CAR transduction, were exposed at day 20 in
culture to NR activators for 24 h. CYP2B6 levels were signiﬁcantly
increased following treatment with the human CAR activator
CITCO; however, CYP2B6 inducibility was only modestly altered in
CAR-transduced cells, relative to already enhanced levels detected
in the empty vector transduced cells (Fig. 3D). Notably, CITCO
signiﬁcantly induced 3A4 expression in the CAR transduced cells.
Relative to the treated empty vector-transduced cells, CITCO expo-
sures increased CYP3A4 expression approximately 13.6-fold
(Fig. 3E). Treatment with RIF, a human PXR activator, appeared to
reverse the effect of CAR transduction on CYP3A4 expression.
CYP2C9 expression was not affected by CITCO treatment, while
RIF increased CYP2C9 expression approximately 4-fold, regardless
of whether the cells were CAR-transduced or uninfected (Fig. 3F).
CAR expression enhances hepatic speciﬁc function of hepatic-like cells
To further characterize the impact of CAR expression on hepatic
differentiation, hepatic-speciﬁc functional endpoints including
Fig. 2. CAR expression enhances hepatic differentiation of hESCs. hESCs were transduced with either empty lentiviral vectors or lentiviral vectors expressing CAR.
Quantitative real-time PCR was performed to determine mRNA levels relative to empty vector-transduced cells at day 3 for the following target genes: (A) CAR, (B) the
hepatic transcription factors, C/EPBα, HNF1α, and HNF4α and, (C) the plasma proteins, alpha-1 antitrypsin, albumin, and α-fetoprotein, and (D) the metabolic enzymes,
HMGCS2, PEPCK, and UGT1A1. Data are from at least two independent trials using hESCs from different passages. n po0.05, compared with empty vector-transduced cells at
day 3; $po0.05, compared with CAR-transduced cells at day 3; #po0.05, compared with empty vector-transduced cells at the same indicated day; ND, not detected.
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albumin secretion and CYP activity assays were performed. CAR
transduced cells exhibited a 2.5-fold increase in albumin secretion
at day 20 when compared to uninfected cells (Fig. 4A). Inducible
activity of CYP3A7 by 5 μM CITCO in CAR over-expressing cells was
also signiﬁcantly higher than that of non-transduced cells (Fig. 4B).
Treatment with 50 mM rifampicin slightly increased the CYP2C9
inducible activity, while CAR overexpression did not further
enhance CYP2C9 inducibility (Fig. 4C).
siRNA-mediated CAR reduction attenuates hepatic differentiation
of hESCs
To further conﬁrm the role of CAR in hepatic differentiation, we
determined whether a reduction in CAR expression might attenuate
the differentiation capacity of hESCs induced to differentiate along a
hepatic lineage. Prior to hepatic induction using our hepatic differ-
entiation protocol, hESCs were transduced with lentiviral particles
expressing a siRNA targeted to CAR (Zamule et al., 2008). CAR mRNA
was substantially reduced in hESCs infected with siRNA-expressing
virus, compared to the cell populations infected with empty virus
(Fig. 5A). The siRNA-mediated reduction of CAR resulted in corre-
sponding reductions of the differentiation-induced enhancements in
expression levels of the hepatic transcription factors, C/EBPα, HNF1α,
HNF4α, and forkhead box A1 (FOXA1) (Fig. 5B), as well as for the
plasma proteins, α-fetoprotein and transthyretin (Fig. 5C).
PXR expression does not enhance hepatic differentiation of hESCs
CAR and PXR share overlapping interactions with certain
chemical activators as well as gene targets, and are related in
primary sequence, sharing 40% sequence homology in the DBD
and 45% in the LBD (Timsit and Negishi, 2007). Thus, we examined
the ability of PXR to enhance the differentiation capacity of hESCs
induced to differentiate along a hepatic lineage. In contrast to CAR
(Fig. 1A), PXR mRNA expression was not increased in hESC-derived
hepatic-like cells (Fig. 6A). Further, PXR mRNA expression in
human fetal liver tissue samples was negligible (Fig. 6B), ﬁndings
conﬁrmed by microarray expression data from a panel of human
tissue generated using U133A and GNF1H chips (publicly available
Fig. 3. Effect of CAR expression on basal and inducible CYP450 mRNA expression. (A–C) hESCs were transduced with either empty lentiviral vectors or CAR lentiviral vectors.
Basal CYP450 mRNA expression at indicated days was detected using real-time PCR during hepatic differentiation. mRNA levels relative to empty lentiviral vector-transduced
cells at day 3 was calculated for the following target genes: (A) CYP2B6, (B) CYP3A4 and, (C) CYP3A7. hESCs serve as a negative control and pooled samples from eight
primary human hepatocyte donors (HH) serve as a positive control. (D–F) empty vector (Hepatic-like) or CAR-transduced cells (Hepatic-likeþCAR) at day 20 were treated
with 0.1% DMSO (solvent control), 50 mM rifampicin or 5 mM CITCO for 24 h. Real-time PCR was used to determine fold change levels relative to empty vector-transduced cells
with DMSO treatment for the following target genes: (D) CYP2B6, (E) CYP3A4, and (F) CYP2C9, respectively. Numerical values denote target gene expression levels of CAR-
transduced cells relative to empty vector-transduced cells. npo0.05, compared with empty vector-transduced cells at day 3; #po0.05, compared with empty vector-
transduced cells at the same indicated day.
Fig. 4. CAR expression enhances albumin secretion and cytochrome P450 activity of differentiated hepatic-like cells. (A) The concentration of human albumin secreted at day
20 was assessed by ELISA. (B and C) Transduced cells at day 20 were treated with 0.1% DMSO (solvent control), the indicated concentrations of CITCO or 50 mM rifampicin for
24 h then CYP3A4/7 or CYP2C9 activity is measured and expressed as relative light units (RLU). Numerical values denote target gene activity of CAR-transduced cells relative
to empty vector-transduced cells. n po0.05, compared with empty vector-transduced cells at day 3; #po0.05, compared with empty vector-transduced cells at the same
indicated day.
F. Chen et al. / Developmental Biology 384 (2013) 155–165160
through the UCSC Genome Browser website http://genome.ucsc.
edu/ (Karolchik et al., 2008; Kent et al., 2002)).
More directly, we determined whether PXR, like CAR, can
function to enhance hepatic differentiation capacity. To this end,
hESCs were transduced with lentiviral vectors expressing PXR and
subsequently stimulated to differentiate along a hepatic lineage.
Indeed, PXR mRNA expression was substantively enhanced in
hESCs infected with PXR-expressing virus, compared to cells
Fig. 5. siRNA-mediated reduction in CAR attenuates hepatic differentiation of hESCs. Prior to induction of hepatic differentiation by culturing for 10 days on collagen-coated
plates, hESCs were transduced with either empty lentiviral vectors (Hepatic-like) or lentiviral vectors expressing a siRNA targeted to CAR (Hepatic-likeþCAR siRNA). Real-
time PCR was performed to determine expression levels relative to low passage number hESCs cultured on hFF feeder layers in hESC media of the following target genes:
(A) CAR, (B) C/EBPα, HNF1α, HNF4α, and FOXA1 and (C) plasma proteins α-fetoprotein and transthyretin. Numerical values denote target gene expression levels of CAR siRNA
cells relative to empty vector-transduced cells. n po0.05. Data are from at least two independent trials using hESCs from different passages.
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Fig. 6. PXR mRNA is expressed at very low levels during hepatic differentiation and PXR does not enhance hepatic differentiation of hESCs. Real-time PCR was performed
using cDNA prepared from (A) HESCs or differentiated stem cells at indicated days, and (B) Human fetal liver tissue or pooled samples from eight primary human hepatocyte
donors (HH). Copy number was calculated based on the standard curve generated by amplifying a dilution series of a standard plasmid DNA containing PXR. (C–E) Real-time
PCR was carried out to determine expression levels relative to low passage number hESCs cultured on hFF feeder layers in hESC media of the following target genes: (C) PXR,
(D) C/EBPα, HNF1α, HNF4α, FOXA1 and (E) α-fetoprotein, transthyretin, and transferrin. Numerical values denote target gene expression levels of PXR-transduced cells
relative to empty vector-transduced cells. n po0.05. Data are from two independent trials using hESCs from different passages.
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infected with empty virus (Fig. 6C). However, in contrast to CAR,
hESCs infected with PXR-expressing virus and subject to hepatic
differentiation actually exhibited decreased expression levels of
the hepatic transcription factors C/EBPα, HNF1α, HNF4α, and
FOXA1 (Fig. 6D) as well as decreased levels of the liver-
generated plasma proteins α-fetoprotein, transthyretin, and trans-
ferrin (Fig. 6E). Therefore the differentiation endpoints impacted
by CAR appeared highly speciﬁc to this receptor.
Discussion
These investigations establish an important functional role for
CAR in human hepatic differentiation. In contrast to the relative
lack of detection and functional role of the related nuclear
receptor, PXR, CAR exhibited maximal expression during the
hepatic speciﬁcation and hepatoblast expansion phases of hESC
differentiation and in fetal liver tissue achieved maximal levels
during the ﬁrst and second trimesters of gestation.
Previous reports have similarly suggested that CAR expression
is increased in hepatic-like cells derived from hESCs (Ek et al.,
2007; Zamule et al., 2011). In addition, CAR activation has been
shown to participate in mammalian postnatal development. Tran-
sient activation of CAR by exposure to mouse CAR-speciﬁc agonist
TCPOBOP on the third day after birth resulted in long-term
epigenetic memory, permanently inducing mouse liver expression
of the CAR target gene, CYP2b10, suggesting that CAR activation
during development permanently alters the capacity for drug
metabolism, and therefore may affect therapeutic responses
(Chen et al., 2012). CAR activation is also necessary for prolifera-
tion and differentiation of postnatal hepatic progenitor cells in
mice, contributing to liver regeneration and recovery after injury
(Yamazaki et al., 2011). To further deﬁne the mechanistic and
functional roles for CAR in the hepatic differentiation process, we
used lentiviral transduction schemes to stably express CAR in
hESCs for extended times in culture. We demonstrate for the ﬁrst
time that stable CAR expression during the early phases of the
hepatic differentiation process activates a variety of hepatic
markers, including the expression of HNF1α, HNF4α, albumin
and CYP enzymes, and also enhances hepatic functional endpoints
such as albumin secretion (Figs. 2 and 4). In these respects, after
24 h of stimulation with 5 mM CITCO, CAR over-expressing cells
elicit a much stronger CYP3A4 induction response (both mRNA
and activity) than empty vector- transduced controls (Figs. 3A and
4B). Conversely, CAR knockdown attenuates the differentiation-
dependent increases in expression of a host of hepatic markers
(Fig. 5).
CAR's speciﬁcity as an activator of the hepatogenesis process
was substantiated by the demonstration that PXR is expressed at
only very low levels during human hepatic differentiation or in
human fetal liver (Fig. 6, A and B) and that neither CYP2C9 mRNA
nor CYP2C9 activity were induced upon exposure to rifampicin, a
prototypical human PXR ligand (Fig. 4C). Rather, PXR is highly
expressed selectively in undifferentiated and early differentiated
stem cells (Fig. 6A). It is interesting that in experiments where PXR
was transduced into developing cells primed for the hepatic
lineage, expression of hepatic differentiation markers was reverted
(Fig. 6, C–E). In these respects, PXR appears to function in the
maintenance of the immature phenotype, rather than a promoter
of stem cell differentiation, as is the case for CAR. This ﬁnding
appears consistent with several previous reports demonstrating
that PXR suppresses the proliferation of cancer cells by up-
regulating cyclin-dependent kinase (CDK) inhibitor p21, that
ectopic PXR expression in neuroblastoma cells results in growth
suppression (Misawa et al., 2005), and that PXR activation alone
has no effect on cell proliferation in mouse liver (Shizu et al.,
2013).
The data provided in the current report suggest that CAR is a
newly identiﬁed factor important in promoting the differentiation
and maturation of hepatic-like cells from human embryonic stem
cells (hESCs), naturally pluripotent cells. In contrast, the Yamanaka
factors, Oct3/4, Sox2, c-Myc, and Klf4, are typically transduced via
viral vectors and then transiently expressed in terminally differ-
entiated cells, often in ﬁbroblasts, where they promote somatic
cell reprogramming to induce pluripotent stem cells (iPSCs)
(Takahashi and Yamanaka, 2006). These iPSCs exhibit morphology
and growth properties of embryonic stem cells and express
embryonic cell marker genes (Takahashi and Yamanaka, 2006).
In these respects, CAR appears to function as a facilitator of the
differentiation of hESCs into hepatic-like cells, while Yamanaka
factors are characterized for their ability to participate in generat-
ing iPSCs derived from terminally differentiated cells.
Although it is noted that CAR's effects as presented in the
current study resulted from the over-expression of CAR and not its
chemical activation, overall the data generated support the con-
tention that in human development from stem cell precursors, the
expression of CAR speciﬁcally functions to integrate and drive the
differentiation and maturation of hepatic-like cells.
Interestingly, data published in abstract form derived from
ChIP-seq analyses conducted in human HepG2 cells indicated that
CAR interacts with several known transcription factor motifs
including HNF4, CEBP-α, AP1 and FOXA (Xiao et al., 2012). More-
over, cistromes of CAR overlap with those of RXRα, HNF-4α, CEBP-
β, and Jun-D in HepG2 cells, suggesting that CAR may collaborate
with other transcription factors to promote gene-speciﬁc regula-
tory cascades. Further studies will be necessary to precisely
delineate these interactions, in particular in the differentiation
context where hepatic transcription factors including HNF1, HNF4
and FOXA have been established for their importance in contri-
buting to hepatic differentiation and maturation.
Given the apparently important role of CAR as an integrator of
human hepatocyte development, it is curious that CAR-knockout
mice exhibit no overt morphological abnormalities of the liver
(Wei et al., 2000). This observation suggests that functional
redundancy exists within the complex scheme of hepatic differ-
entiation, such that compensatory mechanisms are in place to
substitute for CAR's deﬁciency in the null mice. Alternatively,
CAR's role in hepatic differentiation may be species-speciﬁc.
In these respects, the review by Jeong and Mangelsdorf (2009)
summarizes advances in the study of the roles of NRs in ‘stemness’
and early cell lineage commitment in a variety of species. The
discussion provides support for the latter hypothesis, noting
signiﬁcant interspecies differences in the expression proﬁles and
roles of members of the NR superfamily in the maintenance of
pluripotency and differentiation, concluding that NR functions in
these roles is highly species-speciﬁc. The study of Xie et al. (2009)
further supports this hypothesis, demonstrating that while CAR is
increasingly expressed during embryoid body differentiation in
both H1 and H9 human ESC lines, expression of CAR in mouse ESCs
is not detectable at any developmental stage. Microarray expres-
sion data from panels of human and mouse tissue, available
through the UCSC Genome Browser website (http://genome.ucsc.
edu/) (Karolchik et al., 2008; Kent et al., 2002), also document
robust levels of CAR expression in human fetal liver tissue, as
corroborated herein, whereas CAR expression in the mouse
embryo appears negligible. Together, these data offer strong
support for a species-selective role of CAR's function as a regulator
of human hepatocyte development from the stem cell lineage.
In summary, this study deﬁnes a novel role for CAR as a key
regulator of human hepatic differentiation – a complex and
multifaceted process which is yet to be fully elucidated.
F. Chen et al. / Developmental Biology 384 (2013) 155–165 163
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